CAMP (Camp4 Therapeutics) Pre-Tax Income : $-26.76 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Camp4 Therapeutics's pretax income for the three months ended in Dec. 2024 was $-13.28 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-26.76 Mil. Camp4 Therapeutics's pretax margin was -2,036.66%.

During the past 3 years, Camp4 Therapeutics's highest Pretax Margin was -4104.76%. The lowest was -14083.14%. And the median was -11013.27%.

Camp4 Therapeutics Pre-Tax Income Historical Data

The historical data trend for Camp4 Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Pre-Tax Income Chart

Camp4 Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Pre-Tax Income

-44.19

-49.29

-51.79

Camp4 Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial			-11.70	-12.99	-	-13.48	-13.28

Competitive Comparison of Camp4 Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Camp4 Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Camp4 Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Camp4 Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Camp4 Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-53.088	+	-0.033	+	0	+	1.33	+	7.105427357601E-15
	=	-51.79

Camp4 Therapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-14.034	+	0.145	+	0	+	0.61	+	1.7763568394003E-15
	=	-13.28

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.76 Mil.

Camp4 Therapeutics (NAS:CAMP) Pre-Tax Income Explanation

Camp4 Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-13.279	/	0.652
	=	-2,036.66%

During the past 3 years, Camp4 Therapeutics's highest Pretax Margin was -4104.76%. The lowest was -14083.14%. And the median was -11013.27%.

Camp4 Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Camp4 Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA

Website

https://www.camp4tx.com

Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.